Actively Recruiting
Evaluation of Immunogenicity and Safety of mRNA-1283 and mRNA-1273 COVID-19 Variant Vaccines in People 12 Years and Older
Led by ModernaTX, Inc. · Updated on 2026-11-04
600
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the immune response and safety of two mRNA COVID-19 vaccines, mRNA-1283 and mRNA-1273, which contain variant formulations. This phase 4, open-label trial aims to evaluate these vaccines within the current environment of COVID-19, focusing on how well they stimulate neutralizing antibodies against matched variants. Participants will be randomly assigned to receive a single intramuscular injection of either mRNA-1273 or mRNA-1283 on Day 1. Both vaccines are sterile liquids given as one dose. The study measures immune responses and safety outcomes up to Day 29 following vaccination. During the study, participants will have their antibody levels measured on Day 29 to assess the vaccines immune response. Safety will be monitored throughout the study, including recording any adverse events or serious side effects from Day 1 through the end of the study. The total duration from enrollment to last assessment is approximately 29 days.
CONDITIONS
Brief Title
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
Research Team
M
Moderna WeCareTeam
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here